Navigation Links
Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil HCl 23 mg
Date:8/29/2013

WOODCLIFF LAKE, N.J., Aug. 29, 2013 /PRNewswire/ -- Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of generic pharmaceuticals that grants certain rights, including the right to market and offer for sale a generic version of donepezil hydrochloride 23 mg and a non-exclusive license to Eisai Intellectual Property covering donepezil hydrochloride 23 mg, including U.S. Patent No. 8,481,565. This agreement applies to the United States only.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs. Media InquiriesInvestor InquiriesMarcia Diljak

Alex ScottEisai Inc.

Eisai Inc.(201) 746-2236

(201) 746-2177


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Launches New Website Providing Employers with Educational Resource for Obesity Management
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
4. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
5. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
6. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
7. FDA Grants Orphan Drug Status To Eisais Lenvatinib
8. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
9. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
10. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... ... Finally, a bruise cream that really works. Originally designed to reduce ... post-surgical treatment plans of a variety of other procedures including, but not limited to, ... bruising and causes a rapid resolution of bruising and inflammatory changes compared to no ...
(Date:6/24/2016)... ... 2016 , ... Dr. Seema Daulat, a native Texan and University of Texas ... as of July 13, 2016. , Dr. Daulat earned her Doctorate of Medicine (MD) ... volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical school, Dr. ...
Breaking Medicine News(10 mins):